cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00007557.7
title: Available IPD datapackage for study 'A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma'

description: This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.
DOI: 10.5255/ukda-sn-856282
title: Knee Exoskeleton Design and Validation, 2021-2022

description: The project collected quantitative and qualitative data. The quantitative datasets include engineering diagrams for exoskeleton design drawings, sensor data processing algorithms and exoskeleton controlling algorithms. The knee exoskeleton prototype validation data from laboratory trial sessions consisted of quantitative datasets to include knee motion data (knee flexion/ extension data) from participants during different exercises and qualitative datasets including videos and images of participants trying the knee exoskeleton in the laboratory. Due to commercial sensitivity the data cannot be made available.
DOI: 10.6084/m9.figshare.21269748
title: decoding_example_data.mat

description: data
DOI: 10.6084/m9.figshare.21269748.v1
title: decoding_v1.mat

description: data
DOI: 10.6084/m9.figshare.21269748.v2
title: decoding_example_data.mat

description: data
DOI: 10.34848/8bbxga/cekjhs
title: stip_colombia_calls_keywords.tab

description: Variables/Columns year: year in which the call was published tit: title of the call (Spanish) kw: keyword hand-curated from the call asjc code_equivalent: matched ASJC code with the keyword hand-curated from the call asjc name_equivalent: ASJC field asjc code_high c artile: where there is no direct match between the keyword hand curated from the call, these are the journal’s ASJC field codes in which the most cited research article was published in the topic asjc name_high c artile: where there is no direct match between the keyword hand curated from the call, these are the journal’s ASJC field in which the most cited research article was published in the topic
DOI: 10.34848/8bbxga/226zwj
title: network_nodes properties_2015_2018.tab

description: Variables/Columns: asjc field id: ASJC field code asjc field name: ASJC field name asjc area: ASJC area betweenesscentrality: betweenness centrality score
DOI: 10.34848/8bbxga/injaed
title: network_nodes properties_2007_2010.tab

description: Variables/Columns: asjc field id: ASJC field code asjc field name: ASJC field name asjc area: ASJC area betweenesscentrality: betweenness centrality score
DOI: 10.34848/8bbxga/02kkmw
title: network_nodes properties_2019_2022.tab

description: Variables/Columns: asjc field id: ASJC field code asjc field name: ASJC field name asjc area: ASJC area betweenesscentrality: betweenness centrality score
DOI: 10.34848/8bbxga/ltew81
title: network_nodes properties_2011_2014.tab

description: Variables/Columns: asjc field id: ASJC field code asjc field name: ASJC field name asjc area: ASJC area betweenesscentrality: betweenness centrality score
DOI: 10.34848/8bbxga
title: Replication Data for: The Policy is Dead, Long Live the Policy — Unveiling Science Technology and Innovation Policy Priorities and Government Transitions via Network Analysis

description: The following files are available: - The hand curated database of research funding calls keywords published by Colciencias-MinCiencias 2005-2022 (Excel format). - One file for each of the four periods analyzed with the results of the co-word network analysis (nodes ASJC field and area classification and betweenness score) (Excel format).
DOI: 10.25934/pr00007402.10
title: Available IPD datapackage for study 'A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer'

description: This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
DOI: 10.17632/rmdmk3tw46.1
title: evening primrose oil and medical abortion

description: EPO use in medical abortion to shorten the duration of 2nd trimester medical termination of missed misscarriage
DOI: 10.17632/ghkw843k4c.1
title: Article about Human Activity Recognition Using Smartphone and Smartwatch

description: Article about Human Activity Recognition Using Smartphone and Smartwatch
DOI: 10.17632/ktjx6jfsxh.1
title: Metabarcoding dataset of Obama nungara gut contents

description: Metabarcoding dataset of Obama nungara gut contents
DOI: 10.5281/zenodo.7594764
title: Raw Data to "Computational Investigation of Explicit Solvent Effects and Specific Interactions of Hydroxypyrene Photoacids in Acetone, DMSO, and Water"

description: This data is a supplement to the publication entitled "Computational Investigation of Explicit Solvent Effects and Specific Interactions of Hydroxypyrene Photoacids in Acetone, DMSO, and Water" in <em>Physical Chemistry Chemical Physics</em> (DOI: 10.1039/D3CP00800B). It contains the structures (as '.xyz' files) and HF/DFT energies from the quantum chemical (QC) calculations using TURBOMOLE (version 7.6). Additional information on the file structure is given in the README file.
DOI: 10.5281/zenodo.7594763
title: Raw Data to "Computational Investigation of Explicit Solvent Effects and Specific Interactions of Hydroxypyrene Photoacids in Acetone, DMSO, and Water"

description: This data is a supplement to the publication entitled "Computational Investigation of Explicit Solvent Effects and Specific Interactions of Hydroxypyrene Photoacids in Acetone, DMSO, and Water" in <em>Physical Chemistry Chemical Physics</em> (DOI: 10.1039/D3CP00800B). It contains the structures (as '.xyz' files) and HF/DFT energies from the quantum chemical (QC) calculations using TURBOMOLE (version 7.6). Additional information on the file structure is given in the README file.
DOI: 10.25375/uct.22041137
title: Interview transcripts - CCT Intranet Upgrade Project

description: Corporate intranets are an essential technology used by organisations to manage their digital information resources. An effective intranet service must balance the resource requirements of its users with the restrictions of the corporate network as well as coordinate an effective digital information storage and retrieval service. In addition, intranets typically also provide an internal communication channel and serve as a key vehicle for the corporate culture of the organisation. <br> The City of Cape Town municipality’s existing intranet platform is in the process of being migrated to more modern technology, allowing for the redevelopment of key functions including the underlying information architecture, associated site navigation elements, search and site metadata, inter alia. As a member of the intranet’s custodian department, the researcher is well positioned to conduct a study of the existing intranet service offering, and to offer an assessment of improvements needed to meet the needs of the modern digital workplace. <br> The research study examines the role of the corporate intranet as a Knowledge Management (KM) tool, with a focus on iterative improvement by the application of an action research approach. Key areas that are examined include the performance, configuration and management of the network infrastructure; site content management; intranet site structure and design; site navigation; site search and search results performance; the application of site governance and usage policies; the expression of corporate culture through the intranet service; the role of the intranet as a collaboration platform; and the requirements of the modern digital workplace in respect of key services including information retrieval and collaborative tools. <br> The study’s primary research data is drawn from interviews with key users of the corporate intranet via snowball sampling. The resultant qualitative data is interpreted and compared with insights from the KM literature and the researcher’s own institutional knowledge, and areas of improvement are identified. The findings are to be presented to the intranet redevelopment team, and will contribute to improving the CCT corporate intranet service. The study also makes a contribution to existing research in the field of KM, Action Research case literature and intranet design theory.
DOI: 10.25375/uct.22041137.v1
title: Interview transcripts - CCT Intranet Upgrade Project

description: Corporate intranets are an essential technology used by organisations to manage their digital information resources. An effective intranet service must balance the resource requirements of its users with the restrictions of the corporate network as well as coordinate an effective digital information storage and retrieval service. In addition, intranets typically also provide an internal communication channel and serve as a key vehicle for the corporate culture of the organisation. <br> The City of Cape Town municipality’s existing intranet platform is in the process of being migrated to more modern technology, allowing for the redevelopment of key functions including the underlying information architecture, associated site navigation elements, search and site metadata, inter alia. As a member of the intranet’s custodian department, the researcher is well positioned to conduct a study of the existing intranet service offering, and to offer an assessment of improvements needed to meet the needs of the modern digital workplace. <br> The research study examines the role of the corporate intranet as a Knowledge Management (KM) tool, with a focus on iterative improvement by the application of an action research approach. Key areas that are examined include the performance, configuration and management of the network infrastructure; site content management; intranet site structure and design; site navigation; site search and search results performance; the application of site governance and usage policies; the expression of corporate culture through the intranet service; the role of the intranet as a collaboration platform; and the requirements of the modern digital workplace in respect of key services including information retrieval and collaborative tools. <br> The study’s primary research data is drawn from interviews with key users of the corporate intranet via snowball sampling. The resultant qualitative data is interpreted and compared with insights from the KM literature and the researcher’s own institutional knowledge, and areas of improvement are identified. The findings are to be presented to the intranet redevelopment team, and will contribute to improving the CCT corporate intranet service. The study also makes a contribution to existing research in the field of KM, Action Research case literature and intranet design theory.
DOI: 10.6084/m9.figshare.22353097
title: Data.sav

description: Research data for: The mediating role of marital satisfaction in the relationship between mate value discrepancy and intimate partner violence
DOI: 10.34740/kaggle/dsv/4976711
title: Dataset for multimodal transport analytics
DOI: 10.25934/pr00006053.15
title: Available IPD datapackage for study 'A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer'

description: This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
DOI: 10.25934/pr00006052.14
title: Available IPD datapackage for study 'A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer'

description: This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
DOI: 10.25934/pr00005998.6
title: Available IPD datapackage for study 'A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer'

description: This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who have not received prior systemic therapy for metastatic breast cancer (MBC). Participants may continue on study treatment until the development of progressive disease (PD) or the loss of clinical benefit, unacceptable toxicity, and/or consent withdrawal. The Cohort I target sample size is 12 participants for the safety run-in stage and approximately 90 participants in the expansion stage. Each of Cohorts II and III will consist of a safety run-in stage of approximately 15 participants followed by an expansion stage of approximately 15 participants.
DOI: 10.26188/22353124
title: Filaria_database_no_canine

description: filaroidea Db that doesn’t have the dog genome in (the smaller size may be better for some users)
DOI: 10.26188/22353124.v1
title: Filaria_database_no_canine

description: filaroidea Db that doesn’t have the dog genome in (the smaller size may be better for some users)
DOI: 10.25934/pr00006051.16
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer'

description: This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).
DOI: 10.6084/m9.figshare.22353013.v1
title: EARMA+-+RMAs+in+Motion+Survey_March+29,+2023_02.24.zip

description: A survey on mobility within the profession of research managers and administrators.
DOI: 10.25934/pr00005598.12
title: Available IPD datapackage for study 'A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy'

description: This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.
DOI: 10.25934/pr00005796.10
title: Available IPD datapackage for study 'A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer'

description: This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
DOI: 10.25934/pr00005794.20
title: Available IPD datapackage for study 'A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy'

description: This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death−ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
DOI: 10.6084/m9.figshare.22353178
title: Supplemental table 1.docx

description: Supplementary table 1
DOI: 10.6084/m9.figshare.22353178.v1
title: Supplemental table 1.docx

description: Supplementary table 1
DOI: 10.25934/pr00005793.11
title: Available IPD datapackage for study 'A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure'

description: This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure. Participants will be randomized to receive either Atezolizumab 1200 milligram (mg) intravenously every 3 weeks or docetaxel 75 milligram per meter square (mg/m^2) intravenously every 3 weeks. Treatment with Atezolizumab may be continued as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
DOI: 10.25934/pr00005791.8
title: Available IPD datapackage for study 'A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer'

description: This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression. Eligible participants will be categorized in to three groups as follows:   1. Participants with no prior chemotherapy for advanced disease;   2. Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants);   3. Participants who are 2L+ and previously treated for brain metastases.
DOI: 10.25345/c5vt1h061
title: MassIVE MSV000091583 - GlycoNote with iterative decoy searching and open-search component analysis for high-throughput and reliable glycan spectral interpretation--Supplementary-Data
title: Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation. However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research. Here, we develop a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis. GlycoNote supports interpretation of any type of tandem-mass spectrometry glycomic data, performs a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications. We test GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis. An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomics studies. By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
DOI: 10.25934/pr00005997.10
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma'

description: This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.